Literature DB >> 6615690

The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition.

H W Devonshire, I Kong, M Cooper, T P Sloan, J R Idle, R L Smith.   

Abstract

The oxidative O-de-ethylation and aromatic 2-hydroxylation of phenacetin have been investigated in panels of extensive (EM, n = 13) and poor (PM, n = 10) metabolizers of debrisoquine. The EM group excreted in the urine significantly more paracetamol (EM: 40.8 +/- 14.9% dose/0-8 h; PM: 29.2 +/- 8.7% dose/0-8 h, 2P less than 0.05) and significantly less 2-hydroxylated metabolites (EM: 4.7 +/- 2.3% dose/0-8 h; PM: 9.7 +/- 3.5% dose/0-8 h, 2P less than 0.005) than the PM group. Apparent first-order rate constants, calculated from pooled phenotype data, for overall elimination of phenacetin (k) and formation of paracetamol (kml) were higher in the EM group (EM: k = 0.191 +/- 0.151 h-1; kml = 0.091 +/- 0.025 h-1; PM: k = 0.098 +/- 0.035 h-1, 2P less than 0.05, kml = 0.052 +/- 0.019 h-1, 2P less than 0.05) than the PM group. The apparent first-order rate constant for 2-hydroxylation displayed no significant inter-phenotype differences. Correlation analysis demonstrated that genetically determined oxidation status accounted for approximately 50% of the inter-individual variability in phenacetin disposition encountered in this study.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6615690      PMCID: PMC1427984          DOI: 10.1111/j.1365-2125.1983.tb04980.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  27 in total

1.  Migraine as a deadly disease.

Authors:  E ASK-UPMARK
Journal:  Br Med J       Date:  1960-09-17

2.  [Familial chronic bilateral kidney disease].

Authors:  M POLI
Journal:  Helv Med Acta       Date:  1955-05

3.  Polymorphism of carbon oxidation of drugs and clinical implications.

Authors:  T P Sloan; A Mahgoub; R Lancaster; J R Idle; R L Smith
Journal:  Br Med J       Date:  1978-09-02

4.  Genetic impairment of phenformin metabolism.

Authors:  R R Shah; N S Oates; J R Idle; R L Smith
Journal:  Lancet       Date:  1980-05-24       Impact factor: 79.321

5.  Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation.

Authors:  T P Sloan; J R Idle; R L Smith
Journal:  Clin Pharmacol Ther       Date:  1981-04       Impact factor: 6.875

6.  Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.

Authors:  L Bertilsson; H J Dengler; M Eichelbaum; H U Schulz
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

7.  Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver.

Authors:  D S Davies; G C Kahn; S Murray; M J Brodie; A R Boobis
Journal:  Br J Clin Pharmacol       Date:  1981-01       Impact factor: 4.335

8.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

9.  Kinetic considerations relating to the accrual and elimination of drug metabolites.

Authors:  A J Cummings; B K Martin; G S Park
Journal:  Br J Pharmacol Chemother       Date:  1967-02

10.  Genesis of analgesic nephropathy in the United Kingdom.

Authors:  R M Murray
Journal:  Kidney Int       Date:  1978-01       Impact factor: 10.612

View more
  7 in total

Review 1.  Genetics of caffeine consumption and responses to caffeine.

Authors:  Amy Yang; Abraham A Palmer; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2010-06-09       Impact factor: 4.530

2.  Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines.

Authors:  M A Butler; M Iwasaki; F P Guengerich; F F Kadlubar
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

3.  Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.

Authors:  M E Veronese; S McLean
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  The relationship between the acetylator and the sparteine hydroxylation polymorphisms.

Authors:  D Harmer; D A Evans; L C Eze; M Jolly; E J Whibley
Journal:  J Med Genet       Date:  1986-04       Impact factor: 6.318

5.  The genetic control of phenformin 4-hydroxylation.

Authors:  R R Shah; D A Evans; N S Oates; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1985-10       Impact factor: 6.318

Review 6.  P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease.

Authors:  M Murray
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

7.  Poor sulphoxidation ability in patients with food sensitivity.

Authors:  G K Scadding; R Ayesh; J Brostoff; S C Mitchell; R H Waring; R L Smith
Journal:  BMJ       Date:  1988-07-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.